FOLH1 and nonpapillary renal cell carcinoma: Such modifications, perhaps coupled with what could be a truly superior flurophore [40], may render this latest generation of NIR probes even more suitable for FGS in prostate cancer, ccRCC or other PSMA-expressing tumors than existing agents.